Gene Therapy CDMOs with Clean FDA Inspection History

· updated as new inspection, certificate, and trial data enters the platform
32
CDMOs tracked
32
Fully scored
18
With FDA records
90
FDA inspections
229
EMA/MHRA GMP certs

Gene therapy is delivered through viral vectors — AAV, lentiviral, and adenoviral being the three dominant platforms. AAV dominates in vivo systemic delivery (rare disease, ophthalmology, neurology); lentivirus is the workhorse for ex vivo cell engineering including CAR-T; adenoviral vectors remain relevant for vaccines and select gene therapy programs. Most gene therapy CDMOs specialize in one or two vector platforms, and platform experience is the first filter in any sponsor's shortlist.

The ranking below aggregates every CDMO tracked as a gene therapy manufacturer across these platforms. For platform-specific rankings, use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors evaluating end-to-end programs that combine vector manufacturing with downstream cell processing, the <a href="/modality/cell-and-gene-therapy">cell and gene therapy view</a> extends this list with cell therapy CDMOs.

FDA inspection outcomes across these CDMOs: 38 NAI (no action), 52 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (62), Denmark (52), UNITED KINGDOM (45), Austria (39), Germany (19).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
3
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
4
KB
Durham, NC · Boulder, CO
Hiring · 97+ open roles
84.1 98.5 2 insp · 1 GMP 2026-04-01 · VAI Limited —
5
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
6
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
7
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
8
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
9
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
10
NW
Vilnius, LT; Waltham (MA), USA
Hiring · 16 open roles
80.8 100.0 0 insp · 8 GMP None on file Available —
11
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
12
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
13
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
14
BV
Turku, Finland
Hiring · 2 open roles
79.4 99.8 1 insp · 4 GMP 2024-12-19 · VAI — —
15
UM
Boston, MA
78.7 96.7 2 insp · 0 GMP 2025-12-18 · VAI — —
16
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
17
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
18
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
19
ET
Jumet, BE
78.1 100.0 0 insp · 4 GMP None on file — —
20
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
21
CE
Basel, Switzerland
Hiring · 4 open roles
78.1 100.0 0 insp · 1 GMP None on file — —
22
XP
Bristol, United Kingdom
78.1 100.0 0 insp · 1 GMP None on file — —
23
AD
London, United Kingdom
78.1 100.0 0 insp · 2 GMP None on file — —
24
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
25
AG2
San Carlos, CA
77.6 98.8 1 insp · 0 GMP 2025-04-18 · VAI — —
26
VG
San Sebastián, Spain
Hiring · 3 open roles
76.8 100.0 0 insp · 4 GMP None on file Available —
27
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
28
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
29
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
30
RT
Rome, IT
Fully evidenced
71.1 100.0 0 insp · 4 GMP None on file — 1 program
How we score CDMOs →

What to evaluate in a Gene Therapy CDMO

Vector platform match
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.

Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Gene Therapy CDMOs?
Among Gene Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Novartis, Takeda, AGC Biologics. The table above is the full list. CDMOs cannot pay to change a score.
How many Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 18 Gene Therapy CDMOs with FDA inspection records and 229 EMA/MHRA GMP certificates across the group.
What should I look for in a gene therapy CDMO?
Match the vector platform to your program first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, analytics maturity for that vector type, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific detail.
How many gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of AAV, lentiviral, adenoviral, and generally-tagged gene therapy manufacturers. Each is scored independently on the standard four-pillar Signal Score. CDMOs cannot pay to change a score.
Related modalities
AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Adenoviral Vector CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Cell & Gene Therapy Viral Vector